{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (F\u00e1rmaco Antiobesidad 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es AOD-9604?<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) es un p\u00e9ptido sint\u00e9tico de 16 amino\u00e1cidos desarrollado por <strong>Metabolic Pharmaceuticals Ltd<\/strong> (Australia) a finales de la d\u00e9cada de 1990 como un an\u00e1logo estabilizado del fragmento lipol\u00edtico C-terminal de la hormona de crecimiento humana. Secuencia Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, con una extensi\u00f3n de tirosina en el extremo N-terminal que estabiliza el fragmento parental hGH 177\u2013191, y un puente disulfuro intramolecular Cys7\u2013Cys14). F\u00f3rmula molecular C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>actividad lipol\u00edtica y antilipog\u00e9nica<\/strong> de la mol\u00e9cula parental hGH pero no <em>ajuste<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Clase de compuesto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nombre qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604 (\u201cAnti-Obesity Drug 9604\u201d; sin\u00f3nimos: Tyr-hGH 177-191; H-Tyr-(177-191 fragmento de hGH)-OH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3 (referencia can\u00f3nica de Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815,1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (letra \u00fanica: YLRIVQCRSVEGSCGF; 16 amino\u00e1cidos). El puente disulfuro intramolecular Cys7\u2013Cys14 forma una estructura c\u00edclica que imita la geometr\u00eda disulfuro de la regi\u00f3n parental hGH 182\u2013189. La tirosina N-terminal es una adici\u00f3n sint\u00e9tica (no presente en la hGH nativa 177\u2013191) que estabiliza el fragmento frente a la degradaci\u00f3n proteol\u00edtica amino-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Lip\u00f3lisis mecanicamente desacoplada<\/strong>. El AOD-9604 NO se une al receptor de GH (GHR) \u2014 la superficie de uni\u00f3n al GHR de la hGH nativa se encuentra en la porci\u00f3n N-terminal (regi\u00f3n de residuos 1\u2013120), ausente en el fragmento 176\u2013191. Se cree que la actividad lipol\u00edtica\/antilipog\u00e9nica est\u00e1 mediada por la se\u00f1alizaci\u00f3n del receptor \u03b23-adren\u00e9rgico y la activaci\u00f3n directa de la lipasa sensible a hormonas (HSL) de los adipocitos v\u00eda cAMP-PKA. El mecanismo sigue sin estar completamente caracterizado en la literatura publicada \u2014 no hay un \u00fanico receptor confirmado para el fragmento lipol\u00edtico C-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Vida Media Plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 minutos (muy corto \u2014 impulsado por el truncamiento proteol\u00edtico N-terminal a pesar de la tirosina estabilizadora). Esta corta vida media es una de las principales hip\u00f3tesis de por qu\u00e9 el ensayo de obesidad en fase IIb (2007) no alcanz\u00f3 los objetivos de p\u00e9rdida de peso \u2014 el fragmento se degrada antes de que pueda acumularse suficiente exposici\u00f3n al receptor en el tejido diana.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); espectrometr\u00eda de masas MALDI-TOF confirma 1815.1 Da. COA disponible bajo petici\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Soluble en agua bacteriost\u00e1tica, agua est\u00e9ril, PBS y \u00e1cido ac\u00e9tico al 0.1% a \u22655 mg\/mL; f\u00e1cilmente soluble en DMSO a \u226550 mg\/mL para preparaci\u00f3n de stock in vitro. El puente disulfuro Cys7\u2013Cys14 restringe la geometr\u00eda del p\u00e9ptido pero no impide su solubilidad acuosa.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C sin abrir para stock de trabajo a corto plazo; \u221220 \u00b0C para almacenamiento a largo plazo (estable \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Soluci\u00f3n acuosa reconstituida: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. Evitar ciclos repetidos de congelaci\u00f3n-descongelaci\u00f3n de la soluci\u00f3n reconstituida \u2014 el puente disulfuro es estable a un \u00fanico ciclo, pero ciclos acumulativos pueden provocar redistribuci\u00f3n de tioles libres y agregaci\u00f3n parcial.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es AOD-9604?<\/h2>\n<p><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d; CAS 221231-10-3) es un p\u00e9ptido sint\u00e9tico de 16 amino\u00e1cidos desarrollado por <strong>Metabolic Pharmaceuticals Ltd<\/strong> en la Universidad Monash en Melbourne, Australia, a finales de los a\u00f1os 1990. Es un an\u00e1logo estabilizado del fragmento lipol\u00edtico C-terminal de la hormona de crecimiento humana nativa (residuos 177\u2013191), al que se ha a\u00f1adido una tirosina en el extremo N-terminal para ralentizar la degradaci\u00f3n proteol\u00edtica. Secuencia Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), conservando el puente disulfuro intramolecular Cys182\u2013Cys189 de la hGH parental como Cys7\u2013Cys14 dentro de la numeraci\u00f3n del fragmento. Peso molecular 1815.1 g\/mol, f\u00f3rmula emp\u00edrica C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>efectos promotores del crecimiento\/anab\u00f3licos<\/strong> (mediados a trav\u00e9s del receptor de GH, se\u00f1alizaci\u00f3n JAK2\/STAT5 y producci\u00f3n descendente de IGF-1) y <strong>efectos lipol\u00edticos \/ anti-lipog\u00e9nicos<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/es\/hgh-fragment-176-191\/\">Fragmento HGH 176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>El mecanismo de AOD-9604 es uno de los m\u00e1s discutidos en la investigaci\u00f3n de p\u00e9ptidos de HGH:<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>Ausencia de uni\u00f3n al receptor de GH<\/strong> original. Esta es la propiedad farmacol\u00f3gica <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> negativa <em>definitoria y la base de la utilidad de AOD-9604 en investigaci\u00f3n como herramienta para aislar el eje de la lip\u00f3lisis.<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>\u2014 La principal hip\u00f3tesis mecan\u00edstica para la actividad lipol\u00edtica de AOD-9604 es que interact\u00faa con el receptor adren\u00e9rgico \u03b23 (ADRB3) en los adipocitos, ya sea directamente como modulador alost\u00e9rico o a trav\u00e9s de una v\u00eda intermedia. Investigaciones in vitro publicadas han demostrado que el efecto lipol\u00edtico de AOD-9604 se aten\u00faa con antagonistas adren\u00e9rgicos \u03b23, apoyando la hip\u00f3tesis del \u03b23-AR, aunque no se ha demostrado concluyentemente la uni\u00f3n directa de AOD-9604 \/ \u03b23-AR en ensayos de uni\u00f3n con radioligandos. El mecanismo sigue sin estar completamente caracterizado \u2014 una caracter\u00edstica que los investigadores deben tener en cuenta al interpretar los resultados publicados sobre AOD-9604.<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>\u2014 Aguas abajo de la activaci\u00f3n del receptor, se ha reportado que AOD-9604 activa la lipasa sensible a hormonas de los adipocitos mediante fosforilaci\u00f3n mediada por PKA (la ruta can\u00f3nica de activaci\u00f3n de la lip\u00f3lisis), impulsando la hidr\u00f3lisis de triglic\u00e9ridos en glicerol y \u00e1cidos grasos libres. El aumento en la liberaci\u00f3n de \u00e1cidos grasos libres a la circulaci\u00f3n ha sido documentado en trabajos in vivo con roedores despu\u00e9s de la administraci\u00f3n de AOD-9604.<\/strong> \u2014 Downstream of receptor engagement, AOD-9604 has been reported to activate adipocyte hormone-sensitive lipase via PKA-mediated phosphorylation (the canonical lipolysis-activation route), driving triglyceride hydrolysis into glycerol and free fatty acids. The increase in free fatty acid release into circulation has been documented in published rodent in-vivo work after AOD-9604 administration.<\/li>\n<li><strong>Actividad anti-lipog\u00e9nica<\/strong> \u2014 Adem\u00e1s de promover la lip\u00f3lisis, se ha informado que el AOD-9604 suprime la lipog\u00e9nesis de novo en adipocitos cultivados, reduciendo la actividad de la acetil-CoA carboxilasa (ACC) y la sintasa de \u00e1cidos grasos (FAS) en ensayos de diferenciaci\u00f3n 3T3-L1. El perfil combinado de aumento de lip\u00f3lisis\/disminuci\u00f3n de lipog\u00e9nesis es la farmacolog\u00eda can\u00f3nica de \u201cmovilizaci\u00f3n de grasas\u201d que el programa original de Metabolic-Pharmaceuticals fue dise\u00f1ado para abordar.<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>El problema de la semivida de 4 minutos<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacolog\u00eda lipol\u00edtica desacoplada del GHR<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>Farmacolog\u00eda del receptor \u03b23-adren\u00e9rgico (indirecta)<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>Farmacolog\u00eda comparativa frente a HGH 191AA y fragmento HGH 176-191<\/strong> \u2014 las comparaciones publicadas cara a cara del AOD-9604 frente a la HGH de longitud completa y el fragmento 176-191 no estabilizado han caracterizado los perfiles diferenciales de uni\u00f3n al GHR, inducci\u00f3n de IGF-1 y lip\u00f3lisis; el AOD-9604 se sit\u00faa en el extremo \u201csolo lipol\u00edtico, sin eje de crecimiento\u201d de este espectro<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/es\/hgh-fragment-176-191\/\">Fragmento HGH 176-191<\/a> (el fragmento parental no estabilizado \u2014 comparaci\u00f3n directa), <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> (la mol\u00e9cula parental de longitud completa \u2014 para farmacolog\u00eda comparativa), <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo de GHRH \u2014 estimulaci\u00f3n del eje HGH aguas arriba), <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> (an\u00e1logo de GHRH 1-29), y <a href=\"https:\/\/medsbase.com\/es\/mots-c\/\">MOTS-c<\/a> (p\u00e9ptido metab\u00f3lico derivado mitocondrial). Explore el <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">peptides &amp; compounds catalog<\/a>, o consulte el <a href=\"https:\/\/medsbase.com\/es\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> y <a href=\"https:\/\/medsbase.com\/es\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> MedsBase dispone de AICAR en un \u00fanico tama\u00f1o de vial liofilizado calibrado para protocolos t\u00edpicos de investigaci\u00f3n in vivo y de alto rendimiento in vitro. El vial est\u00e1 disponible en formatos de paquetes de 10 o 20 viales:. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cultivo celular in vitro y titulaci\u00f3n in vivo de corta duraci\u00f3n \u2014 ensayos de lip\u00f3lisis en adipocitos 3T3-L1, farmacolog\u00eda de adipocitos primarios, paneles de respuesta a dosis, titulaci\u00f3n murina de cohorte \u00fanica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Comparativa \u2014 AOD-9604 frente al fragmento 176-191 de HGH<\/h2>\n<p>AOD-9604 y <a href=\"https:\/\/medsbase.com\/es\/hgh-fragment-176-191\/\">Fragmento HGH 176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragmento HGH 176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Secuencia (letra \u00fanica)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa; con estabilizaci\u00f3n de Tyr en el extremo N-terminal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa) o LRIVQCRSVEGSCGF (15 aa, sin estabilizar) seg\u00fan el lote del proveedor; consultar el COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815,1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817.06 g\/mol (grado proveedor 16-aa) o 1654 g\/mol (15-aa sin estabilizar)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origen<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd (Universidad Monash, Australia, finales de los 90)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~4 minutos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133 minutos (m\u00e1s corto, menos estable a proteasas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uni\u00f3n al receptor de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno \u2014 no interact\u00faa con el eje GHR\/JAK2\/STAT5\/IGF-1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno \u2014 misma propiedad; ambos son fragmentos desacoplados de GHR<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Historial de ensayos cl\u00ednicos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">El ensayo de fase IIb para obesidad (~500 pacientes, 2007) no alcanz\u00f3 el criterio de valoraci\u00f3n principal; programa discontinuado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No hubo un programa formal de desarrollo cl\u00ednico<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ligeramente preferido para trabajo in vivo debido a su vida media marginalmente m\u00e1s larga; compuesto de referencia para comparaciones estructura-funci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ensayo de lip\u00f3lisis in vitro en cultivos celulares donde la vida media corta es menos limitante<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/es\/hgh-fragment-176-191\/\">Fragmento HGH 176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 \u00bfNecesitas agua BAC?<\/strong> La reconstituci\u00f3n de cualquier vial liofilizado requiere agua bacteriost\u00e1tica est\u00e9ril. Combina este producto con nuestro <a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 vial multidosis de 30 mL, conservado con alcohol benc\u00edlico 0.9%, grado USP.<\/div>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo, congele los viales sin abrir a \u221220 \u00b0C (estable \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). El puente disulfuro Cys7\u2013Cys14 es estable en estado liofilizado y durante un almacenamiento refrigerado breve. Proteger de la luz. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el polvo liofilizado). Para un vial de 2 mg, 1,0 mL de diluyente produce una soluci\u00f3n de trabajo de 2 mg\/mL; 0,5 mL produce 4 mg\/mL. Para un vial de 5 mg, 1,0 mL produce 5 mg\/mL; 2,5 mL produce 2 mg\/mL. Para un vial de 10 mg, 1,0 mL produce 10 mg\/mL (l\u00edmite pr\u00e1ctico de solubilidad en tamp\u00f3n acuoso); 5,0 mL produce 2 mg\/mL. AOD-9604 se disuelve r\u00e1pidamente con un suave giro a temperatura ambiente \u2014 normalmente en 15\u201330 segundos. Una vez reconstituido, almacene el vial a 2\u20138 \u00b0C y \u00faselo en 30 d\u00edas. Proteger de la luz. <strong>Evite ciclos repetidos de congelaci\u00f3n-descongelaci\u00f3n del material reconstituido<\/strong> \u2014 la congelaci\u00f3n-descongelaci\u00f3n acumulativa puede provocar alteraci\u00f3n del puente disulfuro Cys7\u2013Cys14 y agregaci\u00f3n parcial. Deseche si aparece turbidez, part\u00edculas o cambio de color marcado. <\/p>\n<h2>Preguntas frecuentes<\/h2>\n<h3>\u00bfCu\u00e1l es la diferencia entre AOD-9604 y el fragmento 176-191 de HGH?<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/es\/hgh-fragment-176-191\/\">Fragmento HGH 176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>\u00bfEs AOD-9604 lo mismo que HGH?<\/h3>\n<p>No. AOD-9604 es un fragmento sint\u00e9tico de 16 amino\u00e1cidos de la HGH que cubre solo la regi\u00f3n lipol\u00edtica del C-terminal (residuos 176\u2013191 + Tyr N-terminal). La <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>\u00bfPor qu\u00e9 fall\u00f3 el ensayo de fase IIb sobre obesidad?<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>\u00bfCu\u00e1l es el estado regulatorio de AOD-9604 seg\u00fan la WADA?<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre AOD-9604 y los agonistas \u03b23-adren\u00e9rgicos directos como mirabegron?<\/h3>\n<p>Mirabegron y CL-316,243 son <em>directo<\/em> agonistas del receptor \u03b23-adren\u00e9rgico \u2014 mol\u00e9culas peque\u00f1as que se unen al sitio ortot\u00e9rmico del \u03b23-AR y activan la se\u00f1alizaci\u00f3n Gs-cAMP. AOD-9604 es un <em>indirecto<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>S\u00ed \u2014 AOD-9604 apunta a una capa diferente de la biolog\u00eda del eje HGH que la <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> o los an\u00e1logos de GHRH (<a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/es\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>\u00bfPor qu\u00e9 a veces se indica que el AOD-9604 tiene una masa de 1815.1 Da y otras veces de 1817 Da?<\/h3>\n<p>La discrepancia refleja la diferencia entre la masa monoisot\u00f3pica (1815.1 Da, calculada a partir del is\u00f3topo m\u00e1s abundante de cada \u00e1tomo) y la masa molecular promedio (1817.1 Da, calculada a partir de la masa promedio ponderada por los is\u00f3topos naturales de cada \u00e1tomo). Ambas son correctas para la misma mol\u00e9cula. La espectrometr\u00eda de masas MALDI-TOF suele reportar la masa monoisot\u00f3pica para p\u00e9ptidos de este tama\u00f1o; la literatura antigua y algunos proveedores reportan la masa promedio. Para fines de COA, la cifra de 1815.1 Da es el valor de referencia can\u00f3nico de Sigma-Aldrich. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/hgh-fragment-176-191\/\"><strong>Fragmento HGH 176-191<\/strong><\/a> \u2014 Fragmento parental no estabilizado \u2014 hermano mecan\u00edstico directo, lip\u00f3lisis similar desacoplada de GHR<\/li>\n<li><a href=\"\/es\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Mol\u00e9cula parental de longitud completa \u2014 para farmacolog\u00eda comparativa con implicaci\u00f3n del eje GH<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 An\u00e1logo de GHRH \u2014 estimulaci\u00f3n del eje HGH aguas arriba<\/li>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/es\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necesaria para reconstituir cualquier vial liofilizado \u2014 diluyente est\u00e9ril conservado con alcohol benc\u00edlico al 0.9%<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragmento lipol\u00edtico C-terminal hGH 176-191 estabilizado (extensi\u00f3n N-terminal Tyr)<br \/>\n\u2705 Desarrollado por Metabolic Pharmaceuticals Ltd (Universidad Monash, finales de los 90)<br \/>\n\u2705 Desacoplado del GHR \u2014 sin IGF-1, sin JAK2\/STAT5, sin activaci\u00f3n del eje de crecimiento<br \/>\n\u2705 Lipol\u00edtico + anti-lipog\u00e9nico; dependiente de \u03b23-AR (mecanismo no completamente caracterizado)<br \/>\n\u2705 Vida media en plasma de ~4 min; Ensayo de fase IIb en obesidad fallido (2007); MW 1815.1, CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}